Last updated on July 2018

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research


Brief description of study

Primary Objective:

  • To demonstrate equivalence of Gan & Lee Insulin Glargine Injection and Lantus in terms of immunogenicity

Secondary Objective:

  • Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin antibodies (AIA) at baseline who develop confirmed positive AIA up to Week 26

Clinical Study Identifier: NCT03371082

Contact Investigators or Research Sites near you

Start Over

Yehuda Handelsman, MD

Metabolic Institute of America
Tarzana, CA United States
1.33miles
  Connect »

Michael Robinson, MD

California Medical Research Association
Northridge, CA United States
6.03miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.